Contribution of Bone Scintigraphy in the Metastatic Extension Assessment of Prostate Cancer: A Study of 288 Cases in the Nuclear Medicine Department of Idrissa Pouye General Hospital, Dakar
Introduction: Prostate cancer is the most frequently diagnosed male malignancy and the fifth leading cause of cancer death in men worldwide. Since the advent of screening methods such as Prostate Specific Antigen (PSA) assay, digital rectal examination (DRE) and prostate biopsy, its incidence has increased significantly. The aim of our study was to analyse aspects of bone scintigraphy (BS) as part of the metastatic extension assessment of prostate cancer in Senegal. Patients and Methods: This was a retrospective descriptive and analytical study, running from January 1er 2022 to August 31 2023. Patients with histologically confirmed prostate cancer were included. Whole-body scans (WBS) were performed using a dual-head SPECT gamma camera (Mediso Nucline TM Spirit DH-V type), 3 hours after intravenous injection of 8 MBq/kg (555 to 740 MBq) of 99mTc-HMDP. Results: A total of 288 patients with a mean age of 68.37 ± 7.79 years were included. The median total PSA level was 97.6 ng/ml, with 144 patients having a level greater than or equal to 20 ng/ml. All patients had adenocarcinoma, and the Gleason score was available in 202 (70.13%) patients, 75.75% of whom had a score greater than or equal to 7. BS was contributory in 70.48% of cases, with 30.90% positive and 39.58% negative. The result was inconclusive in 85 patients (29.51%). The mean PSA for patients with a positive scan was 190.2 ng/ml and 40.6 ng/ml for those with a negative scan. Multiple metastatic lesions predominated (87.35% of cases). Metastatic lesions occurred preferentially in the axial skeleton, with a proportion of 68% versus 32% in the appendicular skeleton. Classification of bone metastases according to the SOLOWAY score revealed grade I (62.07%), grade II (35.63%) and grade IV (2.30%). Conclusion: In Senegal, prostate cancer is generally diagnosed in men of advanced age. The presence of bone metastases is frequent in its evolution, transforming a curable localized disease into a generalized disease with a compromised prognosis. Bone scintigraphy remains an essential part of the initial work-up and evaluation of response to treatment.
References
[1]
Leslie, S.W., Soon-Sutton, T.L., Sajjad, H. and Siref, L.E. (2023) Prostate Cancer. StatPearls Publishing, Treasure Island. http://www.ncbi.nlm.nih.gov/books/nbk470550/
[2]
Amin Al Olama, A., Dadaev, T., Hazelett, D.J., Li, Q., Leongamornlert, D., Saunders, E.J., et al. (2015) Multiple Novel Prostate Cancer Susceptibility Signals Identified by Fine-Mapping of Known Risk Loci among Europeans. Human Molecular Genetics, 24, 5589-5602. https://doi.org/10.1093/hmg/ddv203
[3]
Cassell, A., Yunusa, B., Jalloh, M., Ndoye, M., Mbodji, M.M., Diallo, A., et al. (2019) Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline. Journal of Oncology, 2019, Article ID: 1785428. https://doi.org/10.1155/2019/1785428
[4]
Szot, W., Kostkiewicz, M., Zajac, J., Owoc, A. and Bojar, I. (2014) Prostate Cancer in Patients from Rural and Suburban Areas—PSA Value, Gleason Score and Presence of Metastases in Bone Scan. Annals of Agricultural and Environmental Medicine, 21, 888-892. https://doi.org/10.5604/12321966.1129953
[5]
Cancer de la Prostate et Facteurs de Risque Cancer Environnement. Cancer Environnement. https://www.cancer-environnement.fr/fiches/cancers/cancer-de-la-prostate/
[6]
Niang, L., Ndoye, M., Ouattara, A., Jalloh, M., Labou, M., Thiam, I., et al. (2013) Cancer de la Prostate: Quelle Prise en Charge au Senegal? Progres en Urologie, 23, 36-41. https://doi.org/10.1016/j.purol.2012.09.002
[7]
Cancer CCS/S Canadienne Du. Metastases Osseuses. Societe Canadienne du Cancer. https://cancer.ca/fr/cancer-information/cancer-types/metastatic/bone-metastases
[8]
Couturier, O.-F., Querellou, S., Reichart, J., Pennec, R.L. and Robin, P. (2023) Scintigraphie Osseuse Monophotonique: Quelle Place Dans la Prise en Charge du Cancer de la Prostate? Médecine Nucléaire, 47, 276-280. https://doi.org/10.1016/j.mednuc.2023.07.007
[9]
Ndong, B., Mbodj, M., Mbaye, G., Ndoye, O., Bathily, E.H., Diouf, L., et al. (2012) Place de la Scintigraphie Osseuse Dans le Bilan D’extension des Metastases des Cancers de la Prostate au Senegal: Etude Preliminaire a Propos de 45 Cas. Medecine Nucleaire, 36, 586-590. https://doi.org/10.1016/j.mednuc.2012.05.012
[10]
Gueye, S., Jalloh, M., Labou, I., Niang, L., Kane, R. and Ndoye, M. (2004) Profil Clinique du Cancer de la Prostate au Senegal. African Journal of Urology, 10, 203-207.
[11]
Ndoye, M., Niang, L., Gandaho, K.I., Jalloh, M., Labou, I. and Gueye, S. (2014) Cancer Avance de la Prostate au Senegal. Aspects Diagnostiques a L’hôpital de Grand Yoff, Progrès en Urologie, 24, 271-275. https://doi.org/10.1016/j.purol.2013.08.317
[12]
Zaman, M.U., Fatima, N. and Sajjad, Z. (2011) Metastasis on Bone Scan with Low Prostate Specific Antigen (≤ 20 ng/ml) and Gleason’s Score (< 8) in Newly Diagnosed Pakistani Males with Prostate Cancer: Should We Follow Western Guidelines. Asian Pacific Journal of Cancer Prevention, 12, 1529-1532.
[13]
Lee, S.H., Chung, M.S., Park, K.K., Yom, C.D., Lee, D.H. and Chung, B.H. (2012) Is It Suitable to Eliminate Bone Scan for Prostate Cancer Patients with PSA ≤ 20 ng/ml? World Journal of Urology, 30, 265-269. https://doi.org/10.1007/s00345-011-0728-6
[14]
Sanjaya, I., Mochtar, C.A. and Umbas, R. (2013) Correlation between Low Gleason Score and Prostate Specific Antigen Levels with Incidence of Bone Metastases in Prostate Cancer Patients: When to Omit Bone Scans? Asian Pacific Journal of Cancer Prevention, 14, 4973-4976. https://doi.org/10.7314/APJCP.2013.14.9.4973
[15]
Mongiat-Artus, P., Peyromaure, M., et al. (2009) Recommandations pour la prise en charge du cancer de la prostate chez l’homme agé: Un travail du comité de cancérologie de l’Association Française d’Urologie. Progrès en Urologie, 19, 810-817. https://doi.org/10.1016/j.purol.2009.02.008
[16]
Bratt, O., Drevin, L., Akre, O., Garmo, H. and Stattin, P. (2016) Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. Journal of the National Cancer Institute, 108, Djw110. https://doi.org/10.1093/jnci/djw110
[17]
Eeles, R., Olama, A., Benlloch, S., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., et al. (2013) Identification of 23 New Prostate Cancer Susceptibility Loci Using the ICOGS Custom Genotyping Array. Nature Genetics, 45, 385-391. https://doi.org/10.1038/ng.2560
[18]
Hemminki, K. (2012) Familial Risk and Familial Survival in Prostate Cancer. World Journal of Urology, 30, 143-148. https://doi.org/10.1007/s00345-011-0801-1
[19]
Lichtenstein, P., Holm, N.V., Verkasalo, P.K., Iliadou, A., Kaprio, J., Koskenvuo, M., et al. (2000) Environmental and Heritable Factors in the Causation of Cancer— Analyses of Cohorts of Twins from Sweden, Denmark, and Finland. New England Journal of Medicine, 343, 78-85. https://doi.org/10.1056/NEJM200007133430201
[20]
Ucci, L.A., Hjelmborg, J.B., Harris, J.R., Czene, K., Havelick, D.J., Scheike, T., et al. (2016) Familial Risk and Heritability of Cancer among Twins in Nordic Countries. JAMA, 315, 68-76. https://doi.org/10.1001/jama.2015.17703
[21]
Schumacher, F.R., Al Olama, A.A., Berndt, S.I., Benlloch, S., Ahmed, M., Saunders, E.J., et al. (2018) Association Analyses of More than 140,000 Men Identify 63 New Prostate Cancer Susceptibility Loci. Nature Genetics, 50, 928-936. https://doi.org/10.1038/s41588-018-0142-8
[22]
Zeegers, M., Nekeman, D., Khan, H., Van Dijk, B., Goldbohm, R., Schalken, J., et al. (2013) Prostate Cancer Susceptibility Genes on 8p21-23 in a Dutch Population. Prostate Cancer and Prostatic Diseases, 16, 248-253. https://doi.org/10.1038/pcan.2013.9
[23]
Diop, O., Bathily, E., Diouf, L.D., Djiboune, A., Kabre, S., Leye, M., et al. (2014) Place de la Scintigraphie Osseuse Dans le Bilan D’extension des Metastases Osseuses du Cancer du Sein au Senegal: Etude Preliminaire a Propos de 40 Cas. Sciences de la Sante, 2, 57-62.
[24]
Salomon, L., Bastide, C., Beuzeboc, P., Cormier, L., Fromont, G., Hennequin, C., et al. (2013) Recommandations en Onco-Urologie 2013 du CCAFU: Cancer de la Prostate. Progres en Urologie, 23, S69-S101. https://doi.org/10.1016/S1166-7087(13)70048-4
[25]
Davin, J., Delmas, V., Lebret, T., Molinie, V., Neuzillet, Y. and Richaud, P. (2006) Cancer de la Prostate a Haut Risque. Progres en Urologie (Paris), 16, 661-670.
[26]
Punnen, S., Cooperberg, M.R., D’Amico, A.V., Karakiewicz, P.I., Moul, J.W., Scher, H.I., et al. (2013) Management of Biochemical Recurrence after Primary Treatment of Prostate Cancer: A Systematic Review of the Literature. European Urology, 64, 905-915. https://doi.org/10.1016/j.eururo.2013.05.025
[27]
Boissier, R. (2011) L’antigene Specifique de la Prostate ou PSA. Progrès en Urologie, 21, 798-800. https://doi.org/10.1016/j.purol.2011.09.004
[28]
Heinisch, M., Dirisamer, A., Loidl, W., Stoiber, F., Gruy, B., Haim, S., et al. (2006) Positron Emission Tomography/Computed Tomography with F-18-Fluorocholine for Restaging of Prostate Cancer Patients: Meaningful at PSA < 5 ng/ml? Molecular Imaging and Biology, 8, 43-48. https://doi.org/10.1007/s11307-005-0023-2
[29]
Huchet, V., Kerrou, K., Balogova, S., Nataf, V., Montravers, F. and Talbot, J.-N. (2008) Tomographie par EMission de Positons et Cancer de la Prostate. Médecine Nucléaire, 32, 409-417. https://doi.org/10.1016/j.mednuc.2008.06.003
[30]
Husarik, D.B., Miralbell, R., Dubs, M., John, H., Giger, O.T., Gelet, A., et al. (2008) Evaluation of [18F]-Choline PET/CT for Staging and Restaging of Prostate Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 35, 253-263. https://doi.org/10.1007/s00259-007-0552-9
[31]
Picchio, M., Giovannini, E. and Messa, C. (2011) The Role of PET/Computed Tomography Scan in the Management of Prostate Cancer. Current Opinion in Urology, 21, 230-236. https://doi.org/10.1097/MOU.0b013e328344e556
[32]
Afshar-Oromieh, A., Avtzi, E., Giesel, F.L., Holland-Letz, T., Linhart, H.G., Eder, M., et al. (2015) The Diagnostic Value of PET/CT Imaging with the 68Ga-Labelled PSMA Ligand HBED-CC in the Diagnosis of Recurrent Prostate Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 42, 197-209. https://doi.org/10.1007/s00259-014-2949-6
[33]
Ceci, F., Uprimny, C., Nilica, B., Geraldo, L., Kendler, D., Kroiss, A., et al. (2015) 68Ga-PSMA PET/CT for Restaging Recurrent Prostate Cancer: Which Factors Are Associated with PET/CT Detection Rate? European Journal of Nuclear Medicine and Molecular Imaging, 42, 1284-1294. https://doi.org/10.1007/s00259-015-3078-6
[34]
Eiber, M., Maurer, T., Souvatzoglou, M., Beer, A.J., Ruffani, A., Haller, B., et al. (2015) Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence after Radical Prostatectomy. Journal of Nuclear Medicine, 56, 668-674. https://doi.org/10.2967/jnumed.115.154153
[35]
Gauthe, M., Belissant, O., Girard, A., Yin, J.Z., Ohnona, J., Cottereau, A.-S., et al. (2017) TEP/TDM et Recidive Biologique D’adenocarcinome Prostatique: Apport du 68Ga-PSMA-11 Lorsque la 18F-Fluorocholine N’est pas Contributive. Progres en Urologie, 27, 474-481. https://doi.org/10.1016/j.purol.2017.04.004
[36]
Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M.S., Murphy, D.G., et al. (2016) Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. European Urology, 70, 926-937. https://doi.org/10.1016/j.eururo.2016.06.021
[37]
Verburg, F.A., Pfister, D., Heidenreich, A., Vogg, A., Drude, N.I., Vöö, S., et al. (2016) Extent of Disease in Recurrent Prostate Cancer Determined by [68Ga] PSMA-HBED-CC PET/CT in Relation to PSA Levels, PSA Doubling Time and Gleason Score. European Journal of Nuclear Medicine and Molecular Imaging, 43, 397-403. https://doi.org/10.1007/s00259-015-3240-1
[38]
Zoungrana, M. (2022) Apport de la Scintigraphie Osseuse au MDP Dans le Bilan D’extension des Tumeurs de L’enfant au Service de Medecine Nucleaire du CHU Yalgado Ouedraogo: A Propos de 21 Cas Colliges de 2012 A 2020. Mémoire du Diplôme d’Etudes Spécialisées de Médecine Nucléaire, Université Cheikh Anta Diop de Dakar (Sénégal), No. 011, 90.
[39]
Debiais, F. (2015) Donnees Epidemiologiques et Cliniques des Metastases Osseuses. Oncologie, 17, 63-68. https://doi.org/10.1007/s10269-015-2488-1
[40]
Paycha, F. and Richard, B. (2001) Exploration Scintigraphique du Squelette. Encyclopedie Medico-Chirurgicale, 30.
[41]
Chaffer, C.L. and Weinberg, R.A. (2011) A Perspective on Cancer Cell Metastasis. Science, 331, 1559-1564. https://doi.org/10.1126/science.1203543
[42]
Giammarile, F. (2006) Bone Scintigraphy; La Scintigraphie Osseuse. Medecine Nucleaire Imagerie Fonctionnelle et Metabolique, 30.
[43]
El Ajmi, W., Hmida, O.B., Limam, K., Hammami, H. and Sellem, A. (2020) Cancer du Sein en Tunisie: Profil Epidemiologique et Depistage des Metastases Osseuses. Medecine Nucleaire, 44, 120. https://doi.org/10.1016/j.mednuc.2020.01.046
[44]
Rajkumar, D., Singh, J. and Devasia, A. (2008) Superscan in Carcinoma Prostate. The Indian Journal of Surgery, 70, 44-45. https://doi.org/10.1007/s12262-008-0012-1
[45]
Soloway, M.S., Hardeman, S.W., Hickey, D., Todd, B., Soloway, S., Raymond, J., et al. (1988) Stratification of Patients with Metastatic Prostate Cancer Based on Extent of Disease on Initial Bone Scan. Cancer, 61, 195-202. https://doi.org/10.1002/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y
